Paradigm Capital Management Inc. NY Takes Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Paradigm Capital Management Inc. NY bought a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 404,001 shares of the medical instruments supplier's stock, valued at approximately $3,701,000. Paradigm Capital Management Inc. NY owned about 1.00% of AngioDynamics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANGO. SBI Securities Co. Ltd. bought a new position in shares of AngioDynamics in the 4th quarter valued at about $28,000. R Squared Ltd acquired a new stake in AngioDynamics in the 4th quarter valued at about $49,000. US Bancorp DE grew its holdings in AngioDynamics by 1,938.0% during the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock worth $61,000 after purchasing an additional 6,376 shares during the period. Quinn Opportunity Partners LLC acquired a new position in AngioDynamics during the fourth quarter worth approximately $92,000. Finally, ProShare Advisors LLC bought a new stake in AngioDynamics in the fourth quarter valued at approximately $100,000. 89.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $16.00 target price (up from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Price Performance

Shares of ANGO opened at $9.59 on Tuesday. The company's 50-day moving average is $9.45 and its 200-day moving average is $9.44. The firm has a market capitalization of $389.42 million, a PE ratio of -1.70 and a beta of 0.58. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. The business had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business's revenue for the quarter was down 4.3% on a year-over-year basis. Analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.